Since the therapeutical effects were driven when ADRB2 and not ADRB1 were blocked, the search for a specific β2-blocker led us to demonstrate that ICI-118,551 (ICI), an almost pure β2-blocker, had the same in vitro potential therapeutic effects as propranolol in CNS-HBs primary cultures [14], VHL-ccRCC primary cells, and the 786-O ccRCC cell line [2]. Here, ADRB2 is linked to nonpapillary renal cell carcinoma.